Depressive Clinical Trials in Atlanta, Georgia
23 recruitingAtlanta, Georgia
Showing 1–20 of 23 trials
Recruiting
Phase 2
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Major Depressive Disorder (MDD)
Draig Therapeutics Ltd300 enrolled40 locationsNCT07300969
Recruiting
Phase 3
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
DepressionDepression - Major Depressive DisorderDepression in Adults+3 more
Cybin IRL Limited330 enrolled67 locationsNCT06793397
Recruiting
Phase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences850 enrolled87 locationsNCT06966401
Recruiting
Phase 2
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
Depressive Disorder, Major
Janssen Research & Development, LLC124 enrolled44 locationsNCT06785012
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Depressive Disorder, Major
Janssen Research & Development, LLC258 enrolled6 locationsNCT07227454
Recruiting
Phase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Depressive Disorder, Major
Janssen Research & Development, LLC752 enrolled205 locationsNCT06559306
Recruiting
Phase 3
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled178 locationsNCT06029439
Recruiting
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Major Depressive Disorder
Xenon Pharmaceuticals Inc.450 enrolled42 locationsNCT07076407
Recruiting
Phase 2
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Sirtsei Pharmaceuticals, Inc.456 enrolled50 locationsNCT06254612
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress
Seaport Therapeutics360 enrolled45 locationsNCT07065240
Recruiting
Phase 2
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
Major Depressive Disorder
AbbVie195 enrolled31 locationsNCT07276997
Recruiting
Phase 3
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Major Depressive Disorder
Neumora Therapeutics, Inc.332 enrolled71 locationsNCT06058039
Recruiting
Phase 2
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Major Depressive Disorder
Autobahn Therapeutics, Inc.230 enrolled50 locationsNCT06633016
Recruiting
Phase 3
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences200 enrolled10 locationsNCT06911112
Recruiting
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Major Depressive Disorder
Xenon Pharmaceuticals Inc.450 enrolled46 locationsNCT06775379
Recruiting
Phase 2
JAK Signaling in Depression
Major Depressive Disorder
Emory University100 enrolled1 locationNCT07003997
Recruiting
Phase 2
ALTO-100 in Bipolar Disorder With Depression (BD-D)
Bipolar Disorder I or II With a Major Depressive Episode
Alto Neuroscience200 enrolled27 locationsNCT06656416
Recruiting
Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Major Depressive Disorder
Intra-Cellular Therapies, Inc.470 enrolled60 locationsNCT05850689
Recruiting
Early Phase 1
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
Major Depressive Disorder
Emory University140 enrolled1 locationNCT05327699
Recruiting
Phase 4
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Major Depressive Disorder
Axsome Therapeutics, Inc.350 enrolled40 locationsNCT06223880